BOSTON (MarketWatch) -- In the wake of its acquisition of vaccine maker Chiron, Swiss conglomerate Novartis said Thursday that it is moving its global vaccine headquarters to Cambridge, Mass., near the site of its global pharmaceuticals research headquarters. The vaccine division had previously been sited at Chiron's old headquarters in Emeryville, Calif. Novartis said that despite the move, it remains committed to the Emeryville location, which will continue to be the home of its global diagnostics business. Novartis added that it plans to build a new flu vaccine manufacturing facility in Holly Springs, NC, which will employ cell-culturing vaccine methods that should significantly cut down production time. The company said it plans to supply more than 30 million doses of flu vaccine to the U.S. market for the current influenza season.
